Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17- O, O -bis-sulfamate

Journal of Medicinal Chemistry

Volumn 53, Issue 7, 2010, Pages 2942-2951

  Jourdan, Fabrice ^a   Leese, Mathew P ^a   Dohle, Wolfgang ^a   Hamel, Ernest ^b   Ferrandis, Eric ^c   Newman, Simon P ^d   Purohit, Atul ^d   Reed, Michael J ^d   Potter, Barry V L ^a  

^a University of Bath   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Institut de Recherche Henri Beaufour   (France)

^d ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 3 O SULFAMOYL 17 METHANESULFONYLMETHYL ESTRONE; 2 ETHYL 3 O SULFAMOYL 17BETA METHANESULFONYLESTRA 1,3,5(10) TRIENE; 2 ETHYL 3 O SULFAMOYL 17BETA O METHANESULFONYLESTRA 1,3,5(10) TRIENE; 2 METHOXY 3 O SULFAMOYL 17BETA O METHANESULFONYLESTRA 1,3,5(10) TRIENE; COLCHICINE; COMBRETASTATIN A4; ESTRADIOL DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; MICROTUBULE ASSEMBLY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLCHICINE; ESTRADIOL; HUMANS; INHIBITORY CONCENTRATION 50; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 77950564911     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm9018806     Document Type: Article

References (37)

1. Leese, M. P.; Hejaz, H. A.; Mahon, M. F.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. A-ring-substituted estrogen-3- O -sulfamates: potent multitargeted anticancer agents J. Med. Chem. 2005, 48, 5243 - 5256
2. Leese, M. P.; Leblond, B.; Smith, A.; Newman, S. P.; Di Fiore, A.; De Simone, G.; Supuran, C. T.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity J. Med. Chem. 2006, 49, 7683 - 7696
3. Purohit, A.; Hejaz, H. A.; Walden, L.; Carthy-Morrogh, L.; Packham, G.; Potter, B. V. L.; Reed, M. J. The effect of 2-methoxyoestrone-3- O -sulphamate on the growth of breast cancer cells and induced mammary tumours Int. J. Cancer 2000, 85, 584 - 589
4. MacCarthy-Morrogh, L.; Townsend, P. A.; Purohit, A.; Hejaz, H. A. M.; Potter, B. V. L.; Reed, M. J.; Packham, G. Differential effects of estrone and estrone-3- O -sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells Cancer Res. 2000, 60, 5441 - 5450
5. Newman, S. P.; Leese, M. P.; Purohit, A.; James, D. R.; Rennie, C. E.; Potter, B. V. L.; Reed, M. J. Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates Int. J. Cancer 2004, 109, 533 - 540
6. Chander, S. K.; Foster, P. A.; Leese, M. P.; Newman, S. P.; Potter, B. V. L.; Purohit, A.; Reed, M. J. In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol Br. J. Cancer 2007, 96, 1368 - 1376
7. Winum, J. Y.; Scozzafava, A.; Montero, J. L.; Supuran, C. T. Sulfamates and their therapeutic potential Med. Res. Rev. 2005, 25, 186 - 228
8. Kesisis, G.; Broxterman, H.; Giaccone, G. Angiogenesis inhibitors. Drug selectivity and target specificity Curr. Pharm. Des 2007, 13, 2795 - 2809
9. Traina, T. A. Bevacizumab in the treatment of metastatic breast cancer Oncology 2009, 23, 327 - 332
10. Kohne, C. H.; Lenz, H. J. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer Oncologist 2009, 14, 478 - 488
11. Mahalingam, D.; Mita, A.; Mita, M. M.; Nawrocki, S. T.; Giles, F. J. Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development Curr. Probl. Cancer 2009, 33, 73 - 111
12. Horn, L.; Sandler, A. B. Angiogenesis in the treatment of non-small cell lung cancer Proc. Am. Thorac. Soc. 2009, 6, 206 - 217
13. Ho, Y. T.; Purohit, A.; Vicker, N.; Newman, S. P.; Robinson, J. J.; Leese, M. P.; Ganeshapillai, D.; Woo, L. W. L.; Potter, B. V. L.; Reed, M. J. Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates Biochem. Biophys. Res. Commun. 2003, 305, 909 - 914
14. Abbate, F.; Winum, J. Y.; Potter, B. V. L.; Casini, A.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase Bioorg. Med. Chem. Lett. 2004, 14, 231 - 234
15. Ireson, C. R.; Chander, S. K.; Purohit, A.; Perera, S.; Newman, S. P.; Parish, D.; Leese, M. P.; Smith, A. C.; Potter, B. V. L.; Reed, M. J. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol- bis-sulphamate in vivo in rodents Br. J. Cancer 2004, 90, 932 - 937
16. Reed, M. J.; Purohit, A.; Woo, L. W. L.; Newman, S. P.; Potter, B. V. L. Steroid sulfatase: molecular biology, regulation, and inhibition Endocr. Rev. 2005, 26, 171 - 202
17. Newman, S. P.; Foster, P. A.; Ho, Y. T.; Day, J. M.; Raobaikady, B.; Kasprzyk, P. G.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A. The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers Br. J. Cancer 2007, 97, 1673 - 1682
18. Newman, S. P.; Foster, P. A.; Stengel, C.; Day, J. M.; Ho, Y. T.; Judde, J. G.; Lassalle, M.; Prevost, G.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells Clin. Cancer Res. 2008, 14, 597 - 606
19. Purohit, A.; Vernon, K. A.; Wagenaar Hummelinck, A. E.; Woo, L. W. L.; Hejaz, H. A.; Potter, B. V. L.; Reed, M. J. The development of A-ring modified analogues of oestrone-3- O -sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity J. Steroid Biochem. Mol. Biol. 1998, 64, 269 - 275
20. Leese, M. P.; Leblond, B.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3- O -sulfamates J. Steroid Biochem. Mol. Biol. 2005, 94, 239 - 251
21. Leese, M. P.; Jourdan, F. L.; Gaukroger, K.; Mahon, M. F.; Newman, S. P.; Foster, P. A.; Stengel, C.; Regis-Lydi, S.; Ferrandis, E.; Fiore, A. D.; De Simone, G.; Supuran, C. T.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents J. Med. Chem. 2008, 51, 1295 - 1308
22. Jourdan, F.; Bubert, C.; Leese, M. P.; Smith, A.; Ferrandis, E.; Regis-Lydi, S.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Effects of C-17 heterocyclic substituents on the anticancer activity of 2-ethylestra-1,3,5(10)-triene-3- O -sulfamates: synthesis, in vitro evaluation and computational modelling Org. Biomol. Chem. 2008, 6, 4108 - 4119
23. Gonschior, M.; Kotteritzsch, M.; Rost, M.; Schonecker, B.; Wyrwa, R. Synthesis of N, N -bis[2-(2-pyridyl)ethyl]amino steroids and related compounds intended as chiral ligands for copper ions Tetrahedron: Asymmetry 2000, 11, 2159 - 2182
24. Okada, M.; Iwashita, S.; Koizumi, N. Efficient general method for sulfamoylation of a hydroxyl group Tetrahedron Lett. 2000, 41, 7047 - 7051
25. Tamura, R.; Kai, Y.; Kakihana, M.; Hayashi, K.; Tsuji, M.; Nakamura, T.; Oda, D. Palladium-catalyzed substitutions of allylic nitrocompounds - regiochemistry J. Org. Chem. 1986, 51, 4375 - 4385
26. Bubert, C.; Leese, M. P.; Mahon, M. F.; Ferrandis, E.; Regis-Lydi, S.; Kasprzyk, P. G.; Newman, S. P.; Ho, Y. T.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 3,17-Disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity J. Med. Chem. 2007, 50, 4431 - 4443
27. Leese, M. P.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumour agents Bioorg. Med. Chem. Lett. 2004, 14, 3135 - 3138
28. Boyd, M. R.; Pauli, K. D. Some practical considerations and applications of the National-Cancer-Institute in vitro anticancer drug discovery screen Drug Dev. Res. 1995, 34, 91 - 109
29. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen Nat. Rev. Cancer 2006, 6, 813 - 823
30. Cushman, M.; He, H. M.; Katzenellenbogen, J. A.; Lin, C. M.; Hamel, E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site J. Med. Chem. 1995, 38, 2041 - 2049
31. D'Amato, R. J.; Lin, C. M.; Flynn, E.; Folkman, J.; Hamel, E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3964 - 3968
32. Hamel, E.; Lin, C. M. Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles Biochemistry 1984, 23, 4173 - 4184
33. Hamel, E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin Cell Biochem. Biophys. 2003, 38, 1 - 22
34. Verdier-Pinard, P.; Lai, J. Y.; Yoo, H. D.; Yu, J.; Marquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells Mol. Pharmacol. 1998, 53, 62 - 76
35. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin Biochemistry 1989, 28, 6984 - 6991
36. Appel, R.; Berger, G. ober das hydrozidosulfamid (On hydrazidosulfamide) Chem. Ber. 1958, 91, 1339 - 1341
37. Woo, L. W. L.; Lightowler, M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism J. Steroid Biochem. Mol. Biol. 1996, 57, 79 - 88